Instrumento Inactivo

Otros idiomas IR-Med Inc. Other OTC

Acciones

IRME

US46265R1032

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

IR-Med Inc.'S PressureSafe Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries	05/04
IR-MED’s PressureSafe™ Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries	05/04
IR-Med Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
IR-Med Inc. and I.R Med Ltd. Appoints Aharon Klein as Interim Chief Executive Officer	05/03
IR-Med Inc. Announces Cessation of Tzur Di-Cori Pursuant as Chief Executive Officer	28/02
IR-Med Inc. Announces Resignation of Inna Martin as Director	23/02
IR-MED Reports 92% Efficacy for PressureSafe™ in Early, Non-Invasive, Skin Color Agnostic Detection of Pressure Injuries	20/02
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16	13/02
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe? Device at NPIAP 2024 Annual Conference on February 16	13/02
IR-MED Awarded Most Innovative Non-Invasive Diagnostics Technology Developer 2023 by Corporate Vision Magazine	21/12
IR-MED Granted Patent in Israel for its AI-Driven Platform Technology: Non-Invasive Analysis of Subcutaneous Tissue	07/12
IR-Med Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
IR-MED Appoints Healthcare Executive and Entrepreneur Tzur Di-Cori as Chief Executive Officer	04/10/23
IR-MED Announces Executive Changes Effective as of October 15, 2023	04/10/23
IR-MED to Conduct Usability Study with Methodist Healthcare of San Antonio for its PressureSafe Device Which is Slated for U.S. Launch in H1 2024	26/09/23
Ir-Med to Conduct Usability Study with Methodist Healthcare of San Antonio for Its Pressuresafe Device Which Is Slated for U.S. Launch in H1 2024	26/09/23
IR-MED Appoints Richard Serbin, Esq. to its Advisory Board	13/09/23
IR-Med Inc. Appoints Richard Serbin, Esq. to Its Advisory Board	13/09/23
IR-MED Chairman & Interim CEO Issues Letter to Shareholders	21/08/23
IR-Med Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas IR-Med Inc. Other OTC

Acciones

IRME

US46265R1032

Otros idiomas

Filtros